JonathanWesleyRiessMD

Oncology • Sacramento, CA

Physician

Join to view full profile

Dr. Riess is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Riess' full profile

Already have an account?

Office
2279 45th St
Sacramento, CA 95817
Phone+1 916-734-5959

Fax+1 916-703-5265

Education & Training

Stanford Health Care-Sponsored Stanford UniversityFellowship, Medical Oncology, 2009 - 2012
University of California (San Francisco)Residency, Internal Medicine, 2006 - 2009
Rutgers Robert Wood Johnson Medical SchoolClass of 2006

Certifications & Licensure

CA State Medical License 2008 - 2026
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2014

Clinical Trials

Pembrolizumab and Trametinib in Treating Patients With Stage IV Non-Small Cell Lung Cancer and KRAS Gene Mutations Start of enrollment: 2018 Jun 26
Active, not recruiting
Phase 1
Rucaparib in Treating Patients With Genomic LOH High and/or Deleterious BRCA1/2 Mutation Stage IV or Recurrent Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial) Start of enrollment: 2019 Apr 16
Active, not recruiting
Phase 2
Testing of the Anti Cancer Drugs CB-839 HCl (Telaglenastat) and MLN0128 (Sapanisertib) in Advanced Stage Non-small Cell Lung Cancer Start of enrollment: 2020 Oct 26
Active, not recruiting
Phase 1

Publications & Presentations

PubMed

Glove Phenomenon Detected by Total-Body PET/CT With 68 GA-DOTATATE.
Hande Nalbant, Clemens Mingels, Fatma Sen, Benjamin A Spencer, Jonathan W Riess
Clinical Nuclear Medicine. 2024-12-01
KRAS G12C Inhibitors: New Drugs, A New Hope.
Surbhi Singhal, Shiruyeh Schokrpur, David Gandara, Jonathan W Riess
Journal of Thoracic Oncology. 2024-12-01
Current Trial Report: A Multicenter Phase I/Ib study of Capmatinib Plus Trametinib in Patients With Metastatic Nonsmall Cell Lung Center Harboring MET Exon 14 Skipping...
Matthew S Lara, Jonathan W Riess, Jonathan W Goldman, Fei Jiang, Trever G Bivona
Clinical Lung Cancer. 2024-12-01

Lectures

Pembrolizumab Exposure-Response Assessments Challenged by Association of Cancer Cachexia and Catabolic Clearance
2019 ASCO Annual Meeting - 6/1/2019

Press Mentions

Commentary: Genetic Components of NSCLC, June 2022June 1st, 2022
Clinical Edge Journal Scan Commentary: Lung Cancer May 2022May 3rd, 2022
The White Ribbon Project Comes to Cancer Center to Shine Light on Deadliest of CancersAugust 25th, 2021
Join now to see all